Scorpion Venom-Derived Voltage-Gated Potassium Channel Blocker Peptides: A Cutting-Edge Therapeutic Frontier in Breast Cancer Research and Beyond

Recent advancements in breast cancer research suggest that potassium channel blocker peptides from scorpion venom could serve as innovative therapies. Ion channels, particularly Voltage-Gated Potassium Channels (VGKCs), are therapeutic targets. They are regularly overexpressed in breast cancer tissues and play critical roles in proliferation, tumor progression, angiogenesis, and apoptosis. VGKCs also affect voltage-sensitive Ca2+ channels by regulating membrane potential and Ca2+ influx, which is vital for processes associated with cancer cell behavior. Scorpion venoms, rich in peptide toxins, specifically target these potassium channels, with the α-KTx family being notable for their high binding affinity and significant influence on therapeutic outcomes. Understanding the mechanisms of these toxins is crucial, primarily because potassium channel dysfunction is associated with various conditions, including cancer. Traditional treatments often prove ineffective for TNBC due to the deficiency of specific receptor expression, highlighting the need for alternative approaches like scorpion venom peptides. The distinctive properties of ion channels, especially the modifiable Kv10.1 and Kv1.3 channels, make them therapeutic targets, as their blockers exhibit anti-proliferative effects. VGKCs play a significant role in cell proliferation and apoptosis, and their modulation by scorpion venom peptides can impact the survival and growth of cancer cells. Additionally, the peptide's interaction with ion channels can alter membrane potential and calcium influx, thereby altering cancer cell behavior. This research lays the groundwork for future studies examining the mechanisms and specificity of scorpion venom-derived peptides, paving the way for translating these findings into clinical advancements in breast cancer therapies.